Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 2Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Merkel Cell 1Carcinoma 1Biochemically Recurrent Prostate Carcinoma 1

Interventions

avelumab 7Nivolumab 5pembrolizumab 4Specimen Handling 3Ipilimumab 3Biopsy 3cemiplimab 2atezolizumab 2Radiotherapy 2Magnetic Resonance Spectroscopy 2tocilizumab 1talimogene laherparepvec 1prednylidene 1poly ICLC 1lutetium Lu 177 dotatate 1lenvatinib 1fludarabine phosphate 1fludarabine 1flt3 ligand protein 1durvalumab 1deltacortene 1Tacrolimus 1Saline Solution 1Radiosurgery 1Radiation 1Prednisone 1MAPRE1 protein, human 1Lutetium-177 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Merkel Cell × Lutetium-177 × Clear all
NCT04261855 2026-03-27

GoTHAM

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Active not recruiting
19 enrolled
DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡